- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Day 2 Recap: Fall Clinical Dermatology Conference for PAs and NPs 2025
Author(s):
Key Takeaways
- Complex drug-induced skin reactions require thorough medication reviews for accurate diagnosis and effective treatment.
- Enhancing practice efficiency involves optimizing workflows, fostering teamwork, and prioritizing clinician well-being.
Catch up on coverage from the second day of the 2025 Fall Clinical Dermatology Conference for PAs and NPs held in Orlando, Florida.
To stay informed with the latest conference insights, subscribe to receive our eNewsletters.
When Medications Masquerade as Skin Disease
Scott Jackson, MD, explores complex drug-induced skin reactions, emphasizing diagnostic challenges and the importance of thorough medication reviews for effective treatment.
Workflow Wins For Even the Busiest Practices
Discover practical strategies for enhancing efficiency, focusing on workflow optimization, teamwork, and clinician well-being for better patient care.
Old-School Systemics Still Pack a Punch
Kristine Kucera, PA-C, MPAS, DHS, highlights the enduring importance of traditional systemic therapies in dermatology, emphasizing their clinical utility amidst emerging treatments.
Gene Expression Profiling as an Emerging Tool in Skin Cancer Management
At this year's Fall Clinical PA/NP meeting, Darrell Rigel, MD, MS, spoke about the evolving role of GEP in managing melanoma and squamous cell carcinoma.
Del Rosso Highlights Next-Gen Treatments
At the Fall Clinical PA/NP 2025 meeting, James Del Rosso, DO, spoke about recently approved therapies like JAKis for alopecia, biologics for AD, and tirbanibulin for AKs.
Stay tuned to Dermatology Times all weekend for exclusive conference coverage and expert insights.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
